Multivariate analysis of risk factors possibly associated with death in a cohort of 194 patients treated by HCT
| Variable/group . | Relative risk of death . | 95% CI . | P . |
|---|---|---|---|
| Year | |||
| Up to 1999 | 1.00 | ||
| Since 2000 | 0.29 | 0.11-0.77 | .013 |
| Age | |||
| Younger than 2 y | 1.00 | ||
| 2-5 y | 0.73 | 0.25-2.11 | .562 |
| Older than 5 y | 2.46 | 0.97-6.19 | .056 |
| Clinical score | |||
| < 3 | 1.00 | ||
| 3 or 4 | 0.86 | 0.17-4.30 | .815 |
| 5 | 1.28 | 0.25-6.41 | .769 |
| Donor | |||
| MSD | 1.00 | ||
| MMFD | 10.5 | 2.20-50.4 | .003 |
| MFD | 7.15 | 0.59-87.3 | .123 |
| URD | 4.56 | 0.91-22.6 | .064 |
| UCB | 9.98 | 1.29-77.1 | .028 |
| Conditioning | |||
| Myeloablative | 1.00 | ||
| Reduced intensity | 1.12 | 0.31-3.99 | .863 |
| Autoimmunity | |||
| No | 1.00 | ||
| Yes | 0.25 | 0.033-1.91 | .182 |
| Acute GVHD (grade III or IV) | |||
| No | 1.00 | ||
| Yes | 1.32 | 0.38-4.58 | .666 |
| Extensive chronic GVHD | |||
| No | 1.00 | ||
| Yes | 0.92 | 0.25-3.33 | .899 |
| Variable/group . | Relative risk of death . | 95% CI . | P . |
|---|---|---|---|
| Year | |||
| Up to 1999 | 1.00 | ||
| Since 2000 | 0.29 | 0.11-0.77 | .013 |
| Age | |||
| Younger than 2 y | 1.00 | ||
| 2-5 y | 0.73 | 0.25-2.11 | .562 |
| Older than 5 y | 2.46 | 0.97-6.19 | .056 |
| Clinical score | |||
| < 3 | 1.00 | ||
| 3 or 4 | 0.86 | 0.17-4.30 | .815 |
| 5 | 1.28 | 0.25-6.41 | .769 |
| Donor | |||
| MSD | 1.00 | ||
| MMFD | 10.5 | 2.20-50.4 | .003 |
| MFD | 7.15 | 0.59-87.3 | .123 |
| URD | 4.56 | 0.91-22.6 | .064 |
| UCB | 9.98 | 1.29-77.1 | .028 |
| Conditioning | |||
| Myeloablative | 1.00 | ||
| Reduced intensity | 1.12 | 0.31-3.99 | .863 |
| Autoimmunity | |||
| No | 1.00 | ||
| Yes | 0.25 | 0.033-1.91 | .182 |
| Acute GVHD (grade III or IV) | |||
| No | 1.00 | ||
| Yes | 1.32 | 0.38-4.58 | .666 |
| Extensive chronic GVHD | |||
| No | 1.00 | ||
| Yes | 0.92 | 0.25-3.33 | .899 |